Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Blood (2022) 140 (Supplement 1): 10185–10188.

https://doi.org/10.1182/blood-2022-162336

Published: 2022

Journal Articles

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Blood (2021) 138 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2021-150311

Published: 2021

Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-140701

Published: 2020

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Heinz Ludwig, MD, Wolfram Pönisch, MD, Stefan Knop, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, MD PhD, Eberhard Gunsilius, MD, Karl Jochen Krenosz, MD, Andreas Petzer, MD, Katja Weisel, MD, Hermann Einsele, MD PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2018) 132 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2018-99-118061

Published: 2018

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Heinz Ludwig, MD, Wolfram Pönisch, MD, Alexander Egle, MD, Stefan Knop, MD, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, Eberhard Gunsilius, Michael A. Fridrik, MD, Andreas Petzer, MD, Katja C. Weisel, Dietger Niederwieser, MD, Axel Hinke, PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2017) 130 (Supplement 1): 1857.

https://doi.org/10.1182/blood.V130.Suppl_1.1857.1857

Published: 2017

Journal Articles

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

Blood (2016) 128 (22): 5692.

https://doi.org/10.1182/blood.V128.22.5692.5692

Published: 2016

Journal Articles

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Heinz Ludwig, MD, Eberhard Gunsilius, MD, Michael Fridrik, MD, Richard Greil, Andreas Petzer, MD, Thomas Kühr, Univ. Doz. Dr., Stefan Knop, MD, Martin Schreder, MD, Elisabeth Rauch, Mag., Wolfram Poenisch, MD, Niklas Zojer, MD

Blood (2016) 128 (22): 3335.

https://doi.org/10.1182/blood.V128.22.3335.3335

Published: 2016

Journal Articles

Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study

Alexander Egle, MD, Lukas Weiss, M.D., Thomas Melchardt, M.D., Eberhard Gunsilius, MD, Andreas L Petzer, M.D., Michael Fridrik, MD, Alois Lang, MD, Otto Krieger, M.D., Josef Thaler, M.D., Richard Greil, MD

Blood (2010) 116 (21): 1380.

https://doi.org/10.1182/blood.V116.21.1380.1380

Published: 2010

Journal Articles

GRP-78 Secreted by Tumor Cells Blocks the Anti-Angiogenic Activity of Bortezomib.

Johann Kern, Gerold Untergasser, PhD, Christoph Zenzmaier, Bettina Sarg, Gunther Gastl, Prof., Dr., Eberhard Gunsilius, M.D., Michael Steurer, MD

Blood (2009) 114 (22): 4805.

https://doi.org/10.1182/blood.V114.22.4805.4805

Published: 2009

Journal Articles

GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib

Johann Kern, Gerold Untergasser, Christoph Zenzmaier, Bettina Sarg, Guenther Gastl, Eberhard Gunsilius, Michael Steurer

Blood (2009) 114 (18): 3960–3967.

https://doi.org/10.1182/blood-2009-03-209668

Published: 2009

Includes: Supplemental data

Journal Articles

Anti-Angiogenic Activity of Bortezomib Is blocked by a 50–60 KDa Protein Secreted by Various tumor Cell Lines

Johann Kern, Gerold Untergasser, PhD, Heinz Zoller, MD, Gunther Gastl, Eberhard Gunsilius, M.D., Michael Steurer, MD

Blood (2008) 112 (11): 5448.

https://doi.org/10.1182/blood.V112.11.5448.5448

Published: 2008

Journal Articles

Vasohibin Inhibits Large Blood Vessel Formation and Supports Development of Microvessels

Johann Kern, Michael Steurer, Gunther Gastl, Eberhard Gunsilius, Gerold Untergasser

Blood (2008) 112 (11): 5450.

https://doi.org/10.1182/blood.V112.11.5450.5450

Published: 2008

Journal Articles

Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study

Alexander Egle, MD, Lukas Weiss, Franz Gassner, Gudrun Russ, Lisa Pleyer, Eberhard Gunsilius, MD, Inge Tinhofer, Josef Thaler, MD, Andreas L. Petzer, MD, Richard Greil

Blood (2008) 112 (11): 3175.

https://doi.org/10.1182/blood.V112.11.3175.3175

Published: 2008

Journal Articles

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Heinz Ludwig, MD, Ivan Spicka, MD, Werner Linkesch, MD, Richard Greil, Hedwig Kasparu, MD, Eberhard Gunsilius, MD, Josef Thaler, MD, Johannes Drach, MD, Ingrid Kuhn, MD, Adalbert Weiβmann, MD, Axel Hinke, PhD

Blood (2008) 112 (11): 3317.

https://doi.org/10.1182/blood.V112.11.3317.3317

Published: 2008

Journal Articles

Maintenance of Telomere Length in Peripheral Blood CD4 + CD25 + Regulatory T-Cells of Cancer Patients Despite Active Proliferation.

Dominik Wolf, MD, Holger Rumpold, MD, Christian Koppelstaetter, MD, Guenther Gastl, MD, Eberhard Gunsilius, MD, Herbert Tilg, MD, Anna M. Wolf, MD

Blood (2005) 106 (11): 3309.

https://doi.org/10.1182/blood.V106.11.3309.3309

Published: 2005

Journal Articles

Cytotoxic Activity of the Proteasome Inhibitor MLN-273 but Not of Bortezomib Is Inhibited by MDR1.

Holger Rumpold, MD, Anna M. Wolf, MD, Gerold Untergasser, PhD, Guenther Gastl, MD, Eberhard Gunsilius, MD, Dominik Wolf, MD

Blood (2005) 106 (11): 4467.

https://doi.org/10.1182/blood.V106.11.4467.4467

Published: 2005

Journal Articles

Stable RNAi-Mediated Knock-Down of P-Glycoprotein by a Transposon-Based Vector System Restores Imatinib Sensitivity.

Holger F. Rumpold, MD, Anna M. Wolf, MD, Guenther A. Gastl, MD, Eberhard Gunsilius, MD, Dominik G.F. Wolf, MD

Blood (2004) 104 (11): 2090.

https://doi.org/10.1182/blood.V104.11.2090.2090

Published: 2004

Journal Articles

Telomerase Activity and Telomere Length of CD4 + CD25 + Regulatory T-Cells under Conditions of In Vitro and In Vivo Expansion.

Dominik G.F. Wolf, MD, Anna M. Wolf, MD, Christian Koppelstaetter, MD, Holger F. Rumpold, MD, Gert Mayer, MD, Guenther A. Gastl, MD, Eberhard Gunsilius, MD, Herbert Tilg, MD

Blood (2004) 104 (11): 3857.

https://doi.org/10.1182/blood.V104.11.3857.3857

Published: 2004

Journal Articles

Breaking the rules? X-ray examination of hematopoietic stem cell grafts at international airports

Andreas L. Petzer, Hans-Georg Speth, Elisabeth Hoflehner, Johannes Clausen, David Nachbaur, Günther Gastl, Eberhard Gunsilius

Blood (2002) 99 (12): 4632–4633.

https://doi.org/10.1182/blood.V99.12.4632

Published: 2002

NARROW

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study

GRP-78 Secreted by Tumor Cells Blocks the Anti-Angiogenic Activity of Bortezomib.

GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib

Anti-Angiogenic Activity of Bortezomib Is blocked by a 50–60 KDa Protein Secreted by Various tumor Cell Lines

Vasohibin Inhibits Large Blood Vessel Formation and Supports Development of Microvessels

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Maintenance of Telomere Length in Peripheral Blood CD4 + CD25 + Regulatory T-Cells of Cancer Patients Despite Active Proliferation.

Cytotoxic Activity of the Proteasome Inhibitor MLN-273 but Not of Bortezomib Is Inhibited by MDR1.

Stable RNAi-Mediated Knock-Down of P-Glycoprotein by a Transposon-Based Vector System Restores Imatinib Sensitivity.

Telomerase Activity and Telomere Length of CD4 + CD25 + Regulatory T-Cells under Conditions of In Vitro and In Vivo Expansion.

Breaking the rules? X-ray examination of hematopoietic stem cell grafts at international airports

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only